WHO Technical Report Series, No. 927, 2005

Average: 8 (1 vote)

2.3.1. Pharmacology

No secondary pharmacodynamic, safety pharmacology or pharmacodynamic drug interaction studies have been conducted with BNT162b2 due to the nature of the RNA-based vaccine product, which is according to applicable guidelines (WHO guideline on nonclinical evaluation of vaccines, WHO Technical Report Series, No. 927, 2005).


WHO Technical Report Series, No. 927, 2005


WHO Guidelines for Assuring the Quality of DNA Vaccines - 1998


Nothing about synthetic ex-vivo RNA for vaccine and may be nothing about lipid capsule!